Company intelligence / Profile preview

CCH Pharmaceuticals

Ownership: Private
Development stage: Phase 2

Overview

The company has completed a Phase 1/2 proof of concept study evaluating the effect of Ketamine Intranasal Spray in the treatment of Chronic Cluster Headache. The study showed that intranasal ketamine is a legitimate pharmacologic treatment that is safe and has proven effective for cluster headache rescue in one case series.

Therapeutic areas: Neurology
Modalities: Small molecules (Ketamine Hydrochloride)
Industry: Biotech

Drug pipeline

1 asset

ketamine

Phase 2

Indications: Cluster headache

Beyond the preview

Go deeper on CCH Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CCH Pharmaceuticals.

Explore the full profile